ArticleFrontiers in nutrition2026
Physicochemical characteristics and anti-colorectal cancer activity of
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: In this study, a novel acidic polysaccharide (SMP-3) was extracted from Results: The purified SMP-3 exhibited a total polysaccharide content of 96.52% with a weight-average molecular weight of 61.3 kDa. Monosaccharide composition analysis revealed that SMP-3 was primarily composed of galacturonic acid, glucuronic acid, glucose, mannose, galactose, and rhamnose in a molar ratio of 52.6:24.1:7.5:6.8:6.0:3.0, preliminarily suggesting a possible pectin-like structural feature with uronic acids accounting for 76.7% of the total content. Structural characterization indicated the presence of both α- and β-glycosidic linkages, an amorphous structure, and an ordered conformation in aqueous solution. Biologically, SMP-3 exhibited dose- and time-dependent cytotoxicity against HCT116 cells while showing minimal toxicity to normal FHC cells. Notably, combination treatment with SMP-3 and REG demonstrated combined effects, significantly enhancing G0/G1 cell cycle arrest, apoptosis induction, and inhibition of cell migration and invasion compared to single-agent treatments. Mechanistically, the combination treatment upregulated p21, Bax, and caspase-3 expression while downregulating cyclin D1, CDK4, and Bcl-2, and profoundly suppressed the phosphorylation of STAT3, AKT, and ERK signaling pathways. Discussion: These findings suggest that SMP-3 possesses distinct structural characteristics and significant anti-tumor efficacy, making it a promising medical food candidate for colorectal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.